MCAM and neuroblastoma: By combining the specific and effective targeting of MCAMhigh NB cells via anti-MCAM-CAR and the enhancement of NK in vivo persistence by NKTR-255, we were able to improve the therapeutic efficacy of NK cells against NB (Figure 3).